Fresenius Kabi has announced the availability of Fulvestrant Injection 250mg/5mL prefilled syringe that is stable at room temperature. The product is bioequivalent to Faslodex (AstraZeneca).
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
The FDA has approved label changes for AstraZeneca‘s Faslodex (fulvestrant) injection. Labeling updates include results and a Kaplan-Meier plot of the final overall survival (OS) analysis from CONFIRM ...
Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
Fresenius Kabi is offering fulvestrant injection in a 250mg per 5mL prefilled syringe. Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, making it ...
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia In this multicenter, ...
A total of 62 patients were initially screened across five study centers for eligibility in this study. Of these, 15 patients were excluded due to various reasons: 10 failed the screening, 3 declined ...
(NYSE:AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results